Technology
New On Robinhood
Upcoming Earnings
Arvinas
$16.489876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$16.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.63 (3.97%) Today
+$0.63 (3.97%) Today
Why Robinhood?
You can buy or sell Arvinas and other stocks, options, ETFs, and crypto commission-free!
About
Arvinas, Inc. Common Stock, also called Arvinas, is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Read More Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
Employees
67
Headquarters
New Haven, Connecticut
Founded
2013
Market Cap
512.76M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
129.51K
High Today
$16.76
Low Today
$15.29
Open Price
$16.41
Volume
39.33K
52 Week High
$25.61
52 Week Low
$10.19
Collections
Technology
New On Robinhood
Upcoming Earnings
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
2018 IPO
News
StreetInsiderMar 25
Arvinas Inc. (ARVN) Commences Initiation of Patient Dosing in First Phase 1 Clinical Trial of PROTAC Protein Degrader, ARV-110
Arvinas, Inc. (NASDAQ: ARVN) today announced the initiation of patient dosing in its Phase 1 clinical trial of ARV-110, the company’s oral androgen receptor (AR)-targeted PROTAC™ protein degrader. The study will evaluate the safety, tolerability, and pharmacokinetics of ARV-110 in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on standard of care therapies. Arvinas believes ARV-110 is the first in a new class of targeted protein degraders to enter human clinical tr...
Price Paid on Robinhood
0% Higher
Right Now
52 Week Low
$10.19
Average Price Paid
$16.46
52 Week High
$25.61
Earnings
-$62.38
-$41.74
-$21.11
-$0.47
Q3 2018
Q4 2018
Estimated
-$0.61 per share
Actual
Expected Mar 27, Pre-Market